Researchers report progress toward a new drug approach that could change the outlook for motor neurone disease (MND) by aiming to shift it from a terminal illness to a chronic condition. All three sources describe the work as targeting a specific immune receptor, suggesting the treatment is designed to modulate immune processes involved in neurodegeneration. The articles do not provide detailed trial results, patient outcomes, or study methodology, but they indicate the research is at an early stage and focuses on developing a drug that can act on the receptor. Each outlet also presents a similar timeline, stating that treatments based on the approach could be available within about five years. While the coverage centers on MND, the sources also mention the possibility that the strategy may have broader relevance for other neurodegenerative diseases. The reported significance of the receptor target is the common thread across the articles, with limited additional information beyond the potential for longer-term disease control and further development.